Cite

HARVARD Citation

    Verstockt, B. et al. (2019). Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. Journal of Crohn's and colitis. pp. 864-872. [Online]. 
  
Back to record